Analysts’ Recent Ratings Updates for TG Therapeutics (TGTX)

A number of research firms have changed their ratings and price targets for TG Therapeutics (NASDAQ: TGTX):

• 11/25/2025 – TG Therapeutics had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – TG Therapeutics had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/13/2025 – TG Therapeutics had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/8/2025 – TG Therapeutics was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 11/4/2025 – TG Therapeutics was upgraded by analysts at B. Riley to a “strong-buy” rating.
• 11/3/2025 – TG Therapeutics had its price target raised by analysts at JPMorgan Chase & Co. from $46.00 to $49.00. They now have an “overweight” rating on the stock.
• 10/8/2025 – TG Therapeutics had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.
• 10/6/2025 – TG Therapeutics is now covered by analysts at HC Wainwright. They set a “buy” rating and a $60.00 price target on the stock.
• 10/6/2025 – TG Therapeutics is now covered by analysts at HC Wainwright. They set a “buy” rating and a $60.00 price target on the stock.

Insiders Place Their Bets

In other news, Director Sagar Lonial sold 20,852 shares of the company’s stock in a transaction on Thursday, September 11th. The stock was sold at an average price of $32.24, for a total transaction of $672,268.48. Following the completion of the sale, the director directly owned 94,061 shares in the company, valued at $3,032,526.64. This represents a 18.15% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Yann Echelard sold 5,000 shares of TG Therapeutics stock in a transaction on Monday, November 24th. The shares were sold at an average price of $32.57, for a total value of $162,850.00. Following the completion of the transaction, the director owned 223,816 shares in the company, valued at $7,289,687.12. The trade was a 2.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 10.64% of the company’s stock.

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.